Advertisement

Topics

GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates / Progress in Multiple Vaccine Programs Including HIV, Zika, Lassa Fever, Malaria, Hepatitis B, and Cancer Immunotherapy

09:01 EST 9 Nov 2017 | FinanzNachrichten

ATLANTA, GA -- (Marketwired) -- 11/09/17 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel viral vector platform technology, announced its finan...

Original Article: GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates / Progress in Multiple Vaccine Programs Including HIV, Zika, Lassa Fever, Malaria, Hepatitis B, and Cancer Immunotherapy

NEXT ARTICLE

More From BioPortfolio on "GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates / Progress in Multiple Vaccine Programs Including HIV, Zika, Lassa Fever, Malaria, Hepatitis B, and Cancer Immunotherapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...